Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145886 · ClinicalTrials.gov registry record · Phase 1
rhPTH Therapy for Low Turnover Bone Fragility
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00145886 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 2 participants.
The verdict
NCT00145886, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.
Interventions
- DRUG rhPTH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2003-02 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145886
The ClinicalTrials.gov registry entry for NCT00145886 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhPTH is the first listed.
NCT00145886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145886 about?
NCT00145886 is a clinical study titled "rhPTH Therapy for Low Turnover Bone Fragility". The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.
What is the current status of trial NCT00145886?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2003-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00145886?
The interventions under investigation include: rhPTH (DRUG).
Who is sponsoring clinical trial NCT00145886?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.